SRPT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 related to the company's gene therapy product, ELEVIDYS, which has been linked to severe safety risks and adverse events [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Dolgicer v. Sarepta Therapeutics, Inc., and it involves purchasers of Sarepta securities from June 22, 2023, to June 24, 2025 [1]. - Sarepta is accused of making false or misleading statements regarding the safety of ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [2][3]. - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [3]. Group 2: Impact on Stock Price - Following the disclosure of a patient's death due to acute liver failure after treatment with ELEVIDYS on March 18, 2025, Sarepta's stock price fell by more than 27% [4]. - On April 4, 2025, after the company announced that EU authorities requested a review of the death, the stock price dropped by over 7% [5]. - A second patient death was reported on June 15, 2025, leading to a further decline in stock price by more than 42% [6]. - On June 24, 2025, the FDA issued a Safety Communication regarding the investigation into the deaths, resulting in an additional stock price drop of over 8% [7]. Group 3: Legal Process and Representation - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [8].